HC Wainwright Estimates VolitionRx's Q3 Earnings (NYSE:VNRX)

Key Points

• HC Wainwright raised their Q3 2025 earnings per share estimate for VolitionRx from ($0.05) to ($0.01), reflecting a more optimistic outlook for the company's financial performance.
• VolitionRx's stock currently holds an average buy rating with a price target of $3.50, despite recent mixed reviews from various analysts regarding the stock's potential.
• Institutional investors are actively trading in VolitionRx, with significant acquisitions reported in the last quarter, indicating growing interest in the company's future prospects.

VolitionRx Limited (NYSE:VNRX - Free Report) - HC Wainwright raised their Q3 2025 earnings per share estimates for shares of VolitionRx in a note issued to investors on Monday, August 18th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.01) per share for the quarter, up from their previous estimate of ($0.05). The consensus estimate for VolitionRx's current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for VolitionRx's FY2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.03) EPS.

A number of other analysts have also weighed in on VNRX. D. Boral Capital reiterated a "buy" rating and issued a $5.00 target price on shares of VolitionRx in a research note on Friday, August 15th. Jones Trading raised VolitionRx to a "strong-buy" rating and set a $3.00 price target on the stock in a research report on Tuesday, June 10th. Finally, Wall Street Zen assumed coverage on VolitionRx in a research report on Thursday, May 15th. They set a "sell" rating on the stock. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, VolitionRx presently has a consensus rating of "Buy" and a consensus target price of $3.50.

VolitionRx Trading Down 3.2%

NYSE:VNRX traded down $0.0220 during midday trading on Wednesday, hitting $0.6660. 129,461 shares of the company traded hands, compared to its average volume of 195,810. The firm's fifty day moving average is $0.71 and its 200-day moving average is $0.59. VolitionRx has a 12-month low of $0.3951 and a 12-month high of $0.94. The firm has a market capitalization of $71.66 million, a P/E ratio of -1.89 and a beta of 1.26.

Institutional Investors Weigh In On VolitionRx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC purchased a new position in shares of VolitionRx in the fourth quarter worth about $36,000. Northern Trust Corp grew its holdings in VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after purchasing an additional 28,579 shares during the period. Lagoda Investment Management L.P. grew its holdings in VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after purchasing an additional 1,481,000 shares during the period. Two Sigma Securities LLC acquired a new stake in VolitionRx in the fourth quarter valued at approximately $29,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in shares of VolitionRx in the second quarter worth approximately $52,000. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Guy Archibald Innes acquired 78,125 shares of the firm's stock in a transaction that occurred on Tuesday, August 5th. The stock was purchased at an average cost of $0.64 per share, for a total transaction of $50,000.00. Following the purchase, the director directly owned 966,814 shares of the company's stock, valued at $618,760.96. This trade represents a 8.79% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Cameron John Reynolds acquired 78,125 shares of the firm's stock in a transaction that occurred on Tuesday, August 5th. The shares were bought at an average price of $0.64 per share, with a total value of $50,000.00. Following the completion of the purchase, the chief executive officer directly owned 2,609,847 shares in the company, valued at $1,670,302.08. The trade was a 3.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 188,750 shares of company stock valued at $118,175 over the last 90 days. 10.40% of the stock is currently owned by company insiders.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.